Hers vs Hims: Same Parent, Two Storefronts Compared

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Welcome to the PlexusDx Education Hub, where we translate GLP-1 science, weight-management options, and the genetics beneath them into decisions you can actually use. Explore the full Peptides & GLP-1 library.

Independent editorial coverage follows. PlexusDx has no affiliate arrangement, sponsorship, or commercial relationship with Hers, Hims, or their shared parent company.

Hers and Hims are an unusual comparison because they share one parent, Hims & Hers Health. So the real question is not which company is bigger but how two storefronts from the same operator differ in practice. This page looks at the shared corporate backbone, the branding split, the common pharmacology, and the genetics neither storefront maps. Market context reflects April 2026.

One company, two front doors

Both Hers and Hims are operated by Hims & Hers Health as subscription telehealth. Each runs a virtual evaluation, provider-issued prescriptions, and dispensing that may be brand-name FDA-approved or compounded semaglutide or tirzepatide through a licensed compounding pharmacy. Because they draw on the same operator, the clinical machinery is closely related; the split is largely one of brand positioning and audience rather than a fundamentally different medical model.

Why the brands are separated at all

The Hers and Hims division is a marketing and audience choice, not a clinical one. Program structures, medication menus, and pricing on each site vary and are published separately, so a plan on one storefront may not match the other dollar for dollar. If you are choosing between them, compare the specific current plans on each site rather than assuming the shared parent makes them identical.

The pharmacology both storefronts share

Whichever front door you use, the compound class is the same. GLP-1 receptor agonists such as semaglutide, liraglutide, and dulaglutide, and the GIP/GLP-1 dual agonist tirzepatide, act on appetite regulation, satiety, and gastric emptying. The mechanism is set by the molecule, not by which sibling brand's checkout you reach. A shared parent does not change that; it simply routes you through two different customer experiences.

The evidence base

The trial record sits with the compounds both brands prescribe. Semaglutide for weight management was studied in STEP (NEJM 2021), tirzepatide in SURMOUNT (NEJM 2022), and tirzepatide for obstructive sleep apnea in SURMOUNT-OSA (NEJM 2024). Effect sizes vary with dose, compound, and population. Neither storefront, nor the parent behind them, alters this evidence.

The layer neither storefront maps

What Hims & Hers cannot capture through either brand is your genetics. A variant in MC4R, central to satiety and energy balance, or in FTO, GLP1R, and TCF7L2, describes the metabolic terrain a GLP-1 compound acts on. These markers are pathway-level and do not predict response to any specific medication. The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including MC4R, FTO, GLP1R, and TCF7L2. With the PlexusDx Weight Management Protocols, offered at $189 for Semaglutide Injection and $289 for Tirzepatide Injection month to month, it is the test before you invest approach, independent of which storefront you would otherwise pick.

No affiliation: PlexusDx has no commercial relationship with Hers or Hims and does not represent either brand.

More from the Education Hub: GLP 1 Receptor Agonist and What Is GLP 1.

Disclaimer: This comparison is educational. PlexusDx is not affiliated with Hers or Hims. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Frequently Asked Questions

Are Hers and Hims the same company?

Yes. Both are operated by Hims & Hers Health as subscription telehealth brands. They share the same corporate parent and a closely related clinical model, but they run separate storefronts with their own branding, audience positioning, program menus, and published pricing that you should compare individually.

If they share a parent, does it matter which I choose?

It can. Program structures, medication options, and pricing are published separately for each brand, so plans may not match dollar for dollar. The shared parent means similar clinical machinery, not identical offers. Compare the current plans on each site directly before deciding which storefront fits your needs.

Does the Precision Peptide Genetic Test favor one brand?

No. It is brand-independent. The test maps pathway-level variants such as MC4R, FTO, and GLP1R that describe your baseline GLP-1 and appetite biology. It does not predict medication response or recommend a storefront; it gives your provider upstream context that applies whichever brand you might choose.

Keep learning at the PlexusDx Education Hub. Return to the Peptides & GLP-1 library.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.